With Serge Lapointe, Ph.D.
The United States Court of Appeals for the Federal Circuit on July 29, 2011 held in a split decision that isolated BRCA 1/2 DNA molecules patented and used by Myriad Genetics Inc. for diagnosing increased breast and ovarian cancer risk are patentable.